European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia

You may not qualify if:

• Pregnant or breast-feeding women, or women planning to become pregnant or breastfeed (excluded by pregnancy test),
• Absence of medically approved contraceptive methods for female of childbearing potential,
• History of very low-calorie diet within 3 months prior to screening visit (lower than 1200 Kcal/day),
• Weight change \> 5 kg within 3 months prior to screening visit,
• History of surgical procedures for weight loss (e.g., stomach stapling, bypass),
• History of bulimia or anorexia nervosa as per DSM-IV criteria
• Presence of any clinically significant endocrine disease according to the investigator, in particular known abnormal TSH and free T4 blood level (Patients treated with thyroid replacement therapy must be on fixed and stable dose for at least 3 months prior to screening and must be in euthyroïd status),
• Established type 1 or 2 diabetes treated, or with at least 2 measures of fasting blood glucose ≥ 126 mg/dl,
• Triglyceride level \> 400 mg/dL (4.52 mmol/L),
• Systolic blood pressure \> 160 mm Hg or diastolic blood pressure \>100 mmHg at screening visit,
• Known severe renal dysfunction (creatinine clearance \< 30 ml/min) or nephrotic syndrome or urinalysis (performed at screening by dipstick) showing 2+ or more protein,
• Known severe hepatic impairment or AST and/or ALT \> 3 times the upper limit of normal at screening,
• Presence of any condition (medical, including clinically significant abnormal laboratory tests, psychological, social or geographical) actual or anticipated that the investigator feels would compromise the patient's safety or limit his/her successful participation to the study. In particular :
• Cardiac abnormalities: cardiac failure status NYHA III or IV, relevant acute abnormal finding seen on ECG at screening or within 6 months before screening,
• Any current malignancy or any cancer within the past five years (except adequately treated basal cell skin cancer or cervix carcinoma in situ),
• +19 more criteria